Premier Therapy.* Premium Platform.** Precise Relief.
Abbott offers the only systems that are FDA-approved to stimulate the dorsal root ganglion (DRG), an effective therapy that provides precise relief for patients suffering from focal chronic pain of the lower limbs due to CRPS.1,2
The Proclaim™ DRG Neurostimulator System provides clinically superior2 therapy on a platform designed for patients’ convenience and comfort.
Advanced neurostimulation technologies
The Proclaim DRG neurostimulator system comes on a premium platform that includes Invisible Therapy™, a system offering discreet and patient-friendly Bluetooth® wireless technology and Apple‡ mobile digital programming. A range of other features enhance patient convenience and comfort, so they can focus on their lives and not on pain.
Longer battery life
The Proclaim DRG neurostimulator system offers a battery life of approximately 6.5 years at nominal settings3 potentially increasing the time between battery replacements and reducing the number of procedures and replacement devices.
Upgradable technology—only from Abbott—allows patients to benefit from advancements without surgery. As new technologies are approved, patients can receive software upgrades, easily and painlessly.
The Proclaim DRG neurostimulator system lets patients and clinicians use wireless programming with convenient and familiar technology. Patients can use the Apple‡ iPod‡ controller to:
- Turn stimulation on and off
- Adjust stimulation settings
- Cycle through programs
- Assess IPG battery longevity
Clinicians can use the clinician programmer, featuring an Apple‡ iPad mini‡ mobile digital device and downloadable programming app, to set programming parameters.
The Proclaim DRG neurostimulator system is MR Conditional, allowing scans of the head and extremities within approved MRI parameters.
DRG stimulation: A clinically proven therapy
DRG stimulation’s effectiveness has been proven in the ACCURATE study, the largest2 randomized clinical trial that compares conventional tonic SCS with DRG stimulation, to treat CRPS in the lower limbs. It has been clinically proven to:
- Provide superior relief over traditional tonic SCS from focal chronic pain2
- Provide persistent pain relief to 86% of patients at 12 months2
- Reduce pain on average of 81.4% at 12 months2
See more clinical evidence.
The Choice For Better Outcomes*
Deliver precise relief to your focal chronic pain patients with the Proclaim DRG neurostimulator system—the choice for achieving superior outcomes* and positive patient experience.
Read more about our approach to chronic pain management.